Source: Eur Respir J 2014; 43: 951-953
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Casanova Crio, Celli Bartolome R.. Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD. Eur Respir J 2014; 43: 951-953

Member's Comments

No comment yet.

Related content which might interest you: Microalbuminuria as a cardiovascular biomarker in patients with COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 Lipocalin-2: a biomarker potentially associated with predisposition to COPD Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019 Year: 2019 ß2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities Source: Eur Respir Monogr 2020; 88: 229-237 Year: 2020 Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Source: Eur Respir J 2015; 46: 846-849 Year: 2015 Mortality risk prediction in COPD by a prognostic biomarker panel Source: Eur Respir J 2014; 44: 1557-1570 Year: 2014 Study of microalbuminuria in COPD patients and its association with cardiac comorbidities Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Pilot: identification of rehospitalization risk factors for patients with COPD Source: Annual Congress 2005 - Assessment and intervention from primary care centre to hospital Year: 2005 Presence of cardiovascular risk markers in OSAS Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea Year: 2007 Frequency of occurrence of risk factors of cardiovascular diseases and assessment of the total cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Cardiovascular risk, subclinical atherosclerosis and markers of systemic inflammation in patients with COPD and frequent exacerbator phenotype Source: International Congress 2016 – Monitoring comorbidities Year: 2016 Comparing non-invasive cardiovascular risk assessment tools in COPD patients: Validation with CV events Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Acute exacerbation in COPD and relationship between cardiovascular risk and functional profile Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings Year: 2018 PP302 – The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension Source: ERS Lung Science Conference 2021 Year: 2021 Identification of novel diagnostic biomarkers of chronic thromboembolic pulmonary hypertension using MALDI-TOF-MS Source: Annual Congress 2010 - Pulmonary hypertension Year: 2010 The association of respiratory health and cardiovascular risk with structural brain disease in patients with COPD Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 Coexisting cardiovascular diseases increase the risk of exacerbations in patients with COPD Source: Annual Congress 2011 - Respiratory epidemiology: comorbidity Year: 2011 Proteomic analysis of plasma from COPD patients and smoking control subjects Source: Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology Year: 2007